Grace Therapeutics GRCE
NASDAQ GRCE
$2.20 +0.06 (+2.80%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Gross Profit (2020 - 2021)

Grace Therapeutics (GRCE) posted Gross Profit of $75000.0 for Q1 2021, up 66.67% sequentially from $45000.0 in Q4 2020.

Grace Therapeutics (GRCE) Gross Profit (2020 - 2021) Analysis & Trends

Grace Therapeutics has reported Gross Profit for 2 years, with the latest figure at $75000.0 in Q1 2021.

  • Quarterly Gross Profit changed N/A year-over-year to $75000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2022 was $120000.0 (changed N/A YoY) and the FY2021 annual result came in at $120000.0, changed N/A from the prior year.
  • Gross Profit improved to $75000.0 in Q1 2021 per GRCE's latest filing, from $45000.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $75000.0 in Q1 2021 and troughed at $45000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Grace Therapeutics 37.99 Mn 37.99 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2021 75,000.00
Mar 31, 2021 75,000.00
Dec 31, 2020 45,000.00
Dec 31, 2020 45,000.00